- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Use of Biologics Reduces Exacerbations, Emergency Visits in Pediatric Asthma
Researchers have found in a new study that Use of Biologics Reduces Exacerbations, Emergency Visits in Pediatric Asthma.
The study has been published in the Annals of Allergy, Asthma & Immunology
Biologic therapy shows potential as an add-on asthma controller, with approval for use in patients ≥6-12 years old and refractory to standard treatment. However, studies showing real-world application and outcomes among the pediatric population are lacking. This study aims to assess characteristics of our pediatric population on biologic therapy, response to prescribed biologics, and reasons for discontinued therapy.
Retrospective chart review of patients on omalizumab, mepolizumab, and dupilumab was performed. Data collected included spirometry (FEV1) and quality of life (ACT) measures, number of ED visits, and asthma exacerbations between 12 months before and after start of therapy. These measures were compared using two-sided statistical analyses with SPSS.26 data software.
Results
54 patients with moderate or severe asthma were reviewed, with majority diagnosed with severe asthma (85%).
Quality of life measures progressively increased over 12 months post-therapy (p=0.024 in moderate asthmatics, p=<0.001 in severe asthmatics).
No significant change was noted in spirometry measures.
Asthma exacerbations and ED visits decreased significantly after starting therapy, (p=0.002; p=0.003, respectively).
Of the 54 patients enrolled, 10 patients stopped therapy, of which 6 failed to respond to therapy and 1 experienced adverse reaction.
The results demonstrate benefits of biologic therapy in moderate-to-severe pediatric asthmatics, with improved quality of life and reduced ED visits and asthma exacerbations within one year of starting therapy.
Reference:
Abernathy S, Moore L, Morales M. Patient characteristics and response to biologic therapies in moderate-to-severe pediatric asthma. Ann Allergy Asthma Immunol. 2022;125(5): S51. doi:10.1016/j.anai.2022.08.644
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751